6 April 2023
INFEX Therapeutics interim results demonstrate a favourable safety and tolerability profile for RESP-X in ongoing Phase I clinical trial
Alderley Park, Cheshire U.K. Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce that RESP-X, the Company’s new anti-virulence therapy to treat Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis bronchiectasis (NCFB) patients, has...
3 April 2023
QV Bioelectronics Awarded £860,000 Innovate UK Boost
31th March 2022, Cheshire, UK - QV Bioelectronics (“QV”), creators of an innovative surgically implanted Electric Field Therapy (EFT) device for the treatment of brain tumours – announces it has been awarded a £860,000 grant under the Combined Investor...
28 March 2023
Monument Therapeutics to present positive data for first clinical study of MT1980, a novel treatment for neuroinflammation
Monument Tx CSO to present positive data from first-in-human clinical study for MT1980, a novel treatment for neuroinflammation, at AD/PD conference March 28 th -April 1 st 2023 … Manchester, UK, March 27th, 2023: Monument Therapeutics, a stratified neuroscience company, today...
9 March 2023
Oxford BioTherapeutics to announce new fully integrated ADC Engine at World ADC Conference 2023
• Engine will combine OBT’s internationally recognised target discovery and ADC development capabilities … • OBT will also present a case study and two abstracts focussing on its recent novel target discovery and high-impact partnership outputs leveraging its proprietary...
8 March 2023
Oxford BioTherapeutics wins Tech Company of the Year and Special Recognition Award
Oxford, UK and San Jose, Calif., 7 March 2023- Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody-Drug Conjugate (ADC)-based therapies, announces it has been honoured with two prestigious awards: the ‘Tech...
1 February 2023
INFEX Therapeutics strengthens Board with appointment of Professor Colm Leonard as a Non-Executive Director
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce the appointment of Professor Colm Leonard as a Non-Executive Director (“NED”) of Infex with immediate effect. Colm will also be chairing Infex’s...
26 January 2023
Healum wins NHS contract for patients at risk of CVD
Cardiovascular disease (CVD) is the single biggest condition where lives can be saved by the NHS over the next decade. There are 7.6 million people living with CVD in the UK, and Cardiovascular Disease is a leading cause of premature disability, mortality, and health...
10 January 2023
QV Bioelectronics raises £2m to develop revolutionary electric field therapy implant for brain tumour treatment
• £2M Pre-Series A financing raised from new and existing VCs. • The funds will facilitate the completion of pre-clinical studies and the further development of GRACE, a first-of-its-kind implanted medical device to treat brain tumour patients with electric field therapy...
9 January 2023
Monument Therapeutics announces first clinical study of MT1980 successfully meets all objectives
Stratified neuroscience company Monument Therapeutics announces first clinical study of MT1980, a novel treatment for neuroinflammation, has successfully met all objectives … Monument Tx announce first-in-human clinical study for MT1980, a novel treatment for neuroinflammation...
5 January 2023
Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has granted Qualified Infectious Disease Product (“QIDP”) designation to MET-X, the...